David Hung

David Hung

Amministratore Delegato presso NUVATION BIO INC.

Patrimonio netto: 289 M $ in data 31/05/2026

68 anni
Health Technology
Finance
Consumer Services

Profilo

David T.
Hung
was the founder of Medivation LLC (California), founded in 1995, serving as President, Chief Executive Officer & Director from 2003 to 2016.
Dr. Hung was the founder of Medivation, Inc., founded in 2003, serving as President, Chief Executive Officer & Director from 2003 to 2016.
Dr. Hung is the founder of Nuvation Bio Operating Co., Inc., founded in 2018, serving as President, Chief Executive Officer & Director since 2018.
Dr. Hung is the founder of Nuvation Bio, Inc., founded in 2018, serving as Chairman, President & Chief Executive Officer since 2024.
Dr. Hung is also the founder of Repharmation, Inc...
Current positions include Chairman at T-Therapeutics Ltd., Independent Director at NovoCure Ltd. since 2018, Director at Establishment Labs SA since 2016, and Director at Auransa, Inc. Former positions include President & Chief Executive Officer at Orion Acquisition Corp.
II; President, Chief Executive Officer & Director at Pro-Duct Health, Inc. from 1999 to 2001; President, Chief Executive Officer & Director at Medivation Neurology LLC from 2011 to 2016; Chief Executive Officer & Director at Sio Gene Therapies, Inc. from 2017 to 2018; Chief Executive Officer & Director at Axovant Sciences, Inc. from 2017 to 2018; Director at Agilvax, Inc.; Director at Solbec Pharmaceuticals Ltd.; Independent Director at Opexa Therapeutics, Inc. from 2010 to 2011; Director at NKT Therapeutics, Inc.; Director at Roivant Sciences GmbH; Independent Director at Establishment Labs Holdings, Inc. from 2016 to 2021; Independent Director at ARYA Sciences Acquisition Corp.
from 2018 to 2021; VP-Lead Discovery, Development & New Projects at Chiron Corp.
from 1996 to 1998; Consultant at Cytyc Health Corp.
in 2003.
Education includes undergraduate degree from Harvard College and doctorate from UCSF School of Medicine.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValutazioneData di valutazione
25/03/2026 59.281.054 ( 17,02% ) 283 M $ 31/05/2026
25/03/2026 1.000.000 ( 6,37% ) 5 M $ 31/05/2026
03/06/2026 32.075 ( 0,03% ) 546 558 $ 31/05/2026

Posizioni attive di David Hung

SocietàPosizioneInizio
NOVOCURE LIMITED Direttore/Membro del Consiglio 31/05/2018
NUVATION BIO INC. Amministratore Delegato 20/03/2018
Fondatore 01/01/2018
Direttore/Membro del Consiglio -
Repharmation, Inc.
Fondatore -
Direttore/Membro del Consiglio 01/02/2016

Precedenti posizioni note di David Hung

SocietàPosizioneFine
ESTABLISHMENT LABS HOLDINGS INC. Direttore/Membro del Consiglio 11/02/2021
ARYA SCIENCES ACQUISITION CORP. Direttore/Membro del Consiglio 01/01/2021
SIO GENE THERAPIES INC. Amministratore Delegato 12/02/2018
░░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
Vedi nel dettaglio l'esperienza di David Hung

Formazione di David Hung

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

54

Relazioni di 1° grado

24

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private24

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Cytyc Health Corp.

Health Technology

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Repharmation, Inc.

Health Technology

Health Technology

  1. Mercati
  2. Insiders
  3. David Hung